Usually, the favorable performance of strategies to inhibit upstream components of STAT3 signaling in preclinical studies cannot be recapitulated in patients with NSCLC, especially when the disease stage is advanced. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.